FDA advisers to weigh first low-dose atropine eye drop for childhood myopia

The Food and Drug Administration will convene its Dermatologic and Ophthalmic Drugs Advisory Committee on 30 October 2026 to review a new drug application for atropine sulfate ophthalmic solution, 0.01%, submitted by Sydnexis, Inc. for slowing the progression of myopia in children 3 years of age or older [s1]. If the drug is ultimately approved, it would be the first prescription eye drop cleared in the United States specifically to slow short-sightedness in children.

The agency published notice of the meeting in the Federal Register on 25 September 2026 [s1]. The committee will discuss NDA 219694, and the session is scheduled to run from 8:30 a.m. to 3 p.m. Eastern Time at the FDA White Oak Campus in Silver Spring, Maryland, with an online option for members of the public to view and participate [s1].

What the committee does and does not decide

An advisory committee does not approve a drug. Its role, as the notice sets out, is to provide advice and recommendations to the FDA on regulatory issues [s1]. The committee will hear the agency's and the sponsor's presentations, question them, and vote on questions the FDA puts to it; the agency then makes the approval decision itself. Advisory committee votes are influential but not binding, and the FDA can and sometimes does depart from them.

The meeting is being held under the Federal Advisory Committee Act [s1]. The FDA said it intends to make the background materials that frame the committee's questions available to the public no later than two business days before the meeting [s1]. Those documents, typically including the agency's own review and the sponsor's briefing package, are where the specifics of the efficacy and safety data will first become public.

The condition at issue

Myopia, or short-sightedness, is a refractive error in which the eye grows too long from front to back, so that distant objects focus in front of the retina rather than on it. It typically begins and advances during childhood, and higher degrees of myopia carry a raised lifetime risk of retinal detachment, glaucoma and myopic maculopathy. Interventions that slow the rate at which a child's myopia worsens aim to limit that eventual severity rather than to correct vision in the way spectacles do.

Low-concentration atropine has been one of the most studied pharmacological approaches. The Low-Concentration Atropine for Myopia Progression (LAMP) study, a randomised, double-blinded, placebo-controlled trial, compared 0.05%, 0.025% and 0.01% atropine eye drops for myopia control in children and is among the trials that established low-dose atropine as an area of active clinical research [s2]. The 0.01% concentration now before the committee sits at the lowest end of that range.

How to comment, and by when

The FDA has established a public docket, numbered FDA-2026-N-10606, for written comment on the meeting [s1]. Comments received on or before 19 October 2026 will be provided to the committee itself; the docket closes on 29 October 2026, and the agency warned that late submissions will not be considered [s1]. The electronic filing system at regulations.gov will accept comments until 11:59 p.m. Eastern Time at the end of 29 October 2026 [s1].

Members of the public who wish to make a formal oral presentation during the open hearing, scheduled for roughly 1 p.m. to 2 p.m. Eastern Time, were asked to notify the agency by 14 October 2026 [s1]. Where more people ask to speak than can be accommodated, the notice says, the FDA may run a lottery to choose the speakers [s1].

What is settled and what is not

What is fixed is procedural: a named product, a named sponsor, a proposed paediatric indication, and a dated public meeting at which an expert committee will advise the agency [s1]. The clinical questions the committee will actually weigh, how well the drops slow myopia progression, how large and durable that effect is, and what the safety profile looks like in young children, depend on the trial data in the briefing materials, which had not been released as of the meeting notice [s1].

Nothing in the notice signals how the agency or its advisers will come down. An advisory committee meeting is a step in the review, not its conclusion. The FDA added that if the meeting is cancelled, it will continue to evaluate the application and any comments submitted to the docket [s1]. For now, the concrete facts are the date, the drug and the question before the panel.

Sources

• [s1] Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments--NDA 219694 for Atropine Sulfate Ophthalmic Solution, 0.01% — U.S. Food and Drug Administration / Federal Register, 25 September 2026.
• [s2] Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control — Ophthalmology (Yam JC et al.), 2019.